Clinical trial · no report yet · Phase 3
NCT06111235
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
- NCT06111235 ↗
- Active not recruiting
- CG Oncology, Inc.
- 15 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 6 | |
| Podcasts | 6 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer; Urothelial Carcinoma
- Interventions
- Cretostimogene Grenadenorepvec; n-dodecyl-B-D-maltoside
- Arms
- Cretostimogene after TURBT · Experimental
- Observation after TURBT · No intervention
- Enrollment
- 367
- Primary outcomes
- Recurrence Free Survival (RFS)
- Sponsor
- CG Oncology, Inc.
- Start
- Dec 14, 2023
- Primary completion
- Nov 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06111235 · updated Jul 1, 2026
Publications
linked from the registry- Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016 Oct;196(4):1021-9. doi: 10.1016/j.juro.2016.06.049. Epub 2016 Jun 16. PubMed 27317986